Aura Biosciences (AURA) vs Zevra Therapeutics (ZVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Aura Biosciences (AURA) has outperformed Zevra Therapeutics (ZVRA) over the past year, gaining 6.8% versus a gain of 5.3%. Aura Biosciences is the larger company by market cap ($678.2 million vs $676.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AURA | ZVRA |
|---|---|---|
| Share price | $6.54 | $11.39 |
| Market cap | $678.23M | $676.38M |
| 1-day change | +0.54% | +3.55% |
| YTD return | +19.36% | +27.12% |
| 1-year return | +6.81% | +5.27% |
| 5-year return | — | +12.59% |
| P/E ratio (TTM) | — | 12.38 |
| Forward P/E | — | 10.58 |
| EPS (TTM) | $-1.75 | $0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.54 | $15.04 |
| 52-week low | $4.73 | $8.01 |
| Distance from 52-week high | -31.41% | -24.24% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +153.82% | +119.49% |
| Average volume | 756.20K | 1.11M |
| Shares outstanding | 103.70M | 59.38M |
| Employees | 113 | 61 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aura Biosciences
AURA stock →Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees
About Zevra Therapeutics
ZVRA stock →Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 61 employees
AURA vs ZVRA FAQ
Which is bigger, Aura Biosciences or Zevra Therapeutics?
Aura Biosciences (AURA) is larger, with a market capitalization of $678.23M compared with $676.38M for Zevra Therapeutics (ZVRA).
Which stock has performed better over the past year, AURA or ZVRA?
AURA returned +6.81% over the past 12 months, compared with +5.27% for ZVRA (price return, excluding dividends). Past performance does not predict future results.
Are Aura Biosciences and Zevra Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Aura Biosciences and Biotechnology: Pharmaceutical Preparations for Zevra Therapeutics.